IFNG and ovarian carcinoma: When compared to controls, the CAM1615HER2 TriKE also showed increased CD107a and IFNγ NK cell activity against a broad panel of ovarian cancer cell lines including OVCAR3 (Figure 3C,D), OVCAR5 (Figure 3E,F), OVCAR8 (Supplementary Figure S3A,B), and OVCAR4 (Supplementary Figure S3C,D) cell lines.